Detail akcie Propanc Biophrm Rg online

Business Summary: Propanc Biopharma, Inc. is an Australia-based biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.
Financial Summary: BRIEF: For the three months ended 30 September 2025, Propanc Biopharma Inc revenues was not reported. Net loss increased from $354K to $4.8M. Higher net loss reflects Administration expenses increase from $221K to $4.6M (expense), Interest expense increase from $86K to $306K (expense), Change in fair value of derivative liabi decrease from $53K (income) to $20K (expense).